GSK Announces Phase I/ii Therapeutic Herpes Simplex Virus Vaccine Trial Fail in 1ry Test

GSK Announces Phase I/ii Therapeutic Herpes Simplex Virus Vaccine Trial Fail in 1ry Test

By, Admin 12 September 2024

GSK announces phase I/II therapeutic herpes simplex virus vaccine trial fails to meet the study’s primary efficacy objective

Overview

GSK plc announced that it has completed the primary objective data analysis from the phase II part of the TH HSV REC-003 trial. This trial is a combined phase I/II proof-of-concept study to assess potential clinical efficacy of GSK3943104, an early-stage therapeutic herpes simplex virus (HSV) vaccine candidate, before progressing it for further clinical development.

Primary Outcome

  • Results show that GSK3943104 did not meet the study’s primary efficacy objective. This vaccine candidate, therefore, will not progress to phase III studies. 
  • No safety concern was observed. 
  • The TH HSV REC-003 study will continue for routine safety monitoring and to generate follow-up data that could offer valuable insights into recurrent genital herpes. GSK is working closely with investigators to inform trial participants.

Need for Innovation For Genital Herpes

  • Given the unmet medical need and burden associated with genital herpes, innovation in this area is still needed. 
  • GSK intends to evaluate the totality of all these data and other studies to progress future research and development of its HSV programme.

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!